{
    "brief_title": "Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer",
    "phase": "",
    "drugs": "['Chidamide', 'Fulvestrant']",
    "drugs_list": [
        "Chidamide",
        "Fulvestrant"
    ],
    "diseases": "['Advanced Breast Cancer']",
    "diseases_list": [
        "Advanced Breast Cancer"
    ],
    "enrollment": "82.0",
    "inclusion_criteria": "inclusion criteria: \n\n women aged \u2265 18 years, histologically or cytologically confirmed HR positive (ER expression \u2265 10%, PR positive or negative), HER2 negative breast cancer patients; \n\n before enrollment for unresectable locally advanced or metastatic breast cancer, and at least one measurable lesion or no measurable lesion and bone metastasis alone patients; \n\n For locally advanced or metastatic breast cancer, no previous endocrine therapy or first-line endocrine therapy, and no previous use of CDK4/6 inhibitors. Specifically, it includes the following conditions: \n\n Cohort 1: (neo) recurrence > 12 months after the end of adjuvant endocrine therapy, and without any rescue therapy \u00b7 newly diagnosed advanced breast cancer without any rescue therapy Cohort 2: (neo) recurrence during or \u2264 12 months after the completion of adjuvant endocrine therapy, and without any rescue therapy \u00b7 recurrence > 12 months after the completion of adjuvant endocrine therapy, and progression by first-line endocrine therapy \u00b7 newly diagnosed advanced breast cancer and progression by first-line endocrine rescue therapy \n\n Cohort 1 without previous chemotherapy for advanced breast cancer; Cohort 2 with \u2264 1 previous chemotherapy for advanced breast cancer; \n\n no brain metastasis or asymptomatic brain metastasis; \n\n ECOG score 0-1; \n\n Absolute neutrophil count \u2265 1.5 \u00d7 109/L, platelet \u2265 100 \u00d7 109/L, hemoglobin \u2265 90 g/L; \n\n Expected survival time \u2265 3 months; \n\n Voluntarily participate in this clinical trial, sign the written informed consent; \n\n ",
    "exclusion_criteria": ": \n\n no measurable lesions (except bone metastases alone), such as pleural or pericardial exudates, ascites, etc. \n\n Patients who have undergone major surgical procedures or significant trauma before enrollment, or are expected to undergo major surgical treatment \n\n Patients who have previously been treated with CDK4/6 inhibitors, fulvestrant or HDAC inhibitors (including romidepsin, vorinostat, berlistat, parabrestat), but have received 1 cycle (\u2264 2 times, on d1, d15, respectively) of fulvestrant within 28 days (before enrollment) are allowed \n\n Known history of allergy to the drug components of this protocol \n\n Meningeal metastasis before enrollment \n\n Uncontrollable serosal effusion \n\n Active infection [an active bacterial, viral, fungal, mycobacterial, parasitic or other infection (excluding fungal infections of the nail bed) within 4 months prior to Screening or any major infectious event requiring intravenous antibiotics, or targeted antiviral therapy, or hospitalization], or persistent fever within 14 days prior to Screening \n\n a history of immunodeficiency, including HIV test positive, or suffering from other acquired, congenital immunodeficiency diseases, or a history of organ transplantation; \n\n according to the investigator's judgment, there are serious hazards to the patient's safety, or affect the patient to complete the study of concomitant diseases (such as: severe hypertension, diabetes, thyroid disease, active infection, etc.); \n\n History of definite neurological or psychiatric disorders, including epilepsy or dementia \n\n Subjects who, in the opinion of the investigator, are not suitable for the study",
    "brief_summary": "This is a Open-label study of chidamide in combination with fulvestrant for the treatment of postmenopausal women with hormone receptor positive, Her2 negative, advanced breast cancer who have received no or only one line of endocrine therapy for advanced breast cancer.",
    "NCT_ID": "NCT05047848"
}